802 results on '"Cohen, Roger B."'
Search Results
2. Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC)
3. Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation
4. Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer
5. Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors
6. Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation
7. The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC
8. Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression
9. The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
10. Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System
11. Identifying predictors of HPV‐related head and neck squamous cell carcinoma progression and survival through patient‐derived models
12. Death without progression as an endpoint to describe cardiac radiation effects in locally advanced non-small cell lung cancer
13. Features of HPV+ OPSCC predictive of recurrence identified by transcriptional profiling of a case-control cohort.
14. A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study.
15. Barriers to physical activity: a study of academic and community cancer survivors with pain
16. Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma
17. Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non–squamous Non–small Cell Lung Cancer After Progression on Platinum and Pemetrexed
18. Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy
19. A benchmark for oncologic outcomes and model for lethal recurrence risk after transoral robotic resection of HPV-related oropharyngeal cancers
20. Sex-based differences in outcomes among surgically treated patients with HPV-related oropharyngeal squamous cell carcinoma
21. Brief Report: Impact of reflex testing on tissue-based molecular genotyping in patients with advanced non-squamous non-small cell lung cancer
22. Acute hospitalizations after proton therapy versus intensity‐modulated radiotherapy for locally advanced non–small cell lung cancer in the durvalumab era
23. Definitive tumor directed therapy confers a survival advantage for metachronous oligometastatic HPV-associated oropharyngeal cancer following trans-oral robotic surgery
24. Oncologic and survival outcomes for resectable locally-advanced HPV-related oropharyngeal cancer treated with transoral robotic surgery
25. Outcomes in Patients With Non–small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy
26. A Phase 2 Trial of Alternative Volumes of Oropharyngeal Irradiation for De-intensification (AVOID): Omission of the Resected Primary Tumor Bed After Transoral Robotic Surgery for Human Papilloma Virus–Related Squamous Cell Carcinoma of the Oropharynx
27. Early Tumor and Nodal Response in Patients with Locally Advanced Non-Small Cell Lung Carcinoma Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy
28. Plunging into the PACIFIC: Outcomes of Patients with Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation
29. The Effective Radiation Dose to Immune Cells Predicts Lymphopenia and Inferior Cancer Control in Locally Advanced NSCLC
30. Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation
31. Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors
32. Impact of telemedicine adoption on accessibility and time to treatment in patients with thoracic malignancies during the COVID-19 pandemic
33. Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series
34. Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens
35. Patterns of Failure in Metastatic NSCLC Treated with First Line Pembrolizumab and Use of Local Therapy in Patients with Oligoprogression
36. Phase II trial of consolidation pembrolizumab after proton reirradiation for thoracic recurrences of non-small cell lung cancer
37. Association Between Duration of Immunotherapy and Overall Survival in Advanced Non–Small Cell Lung Cancer
38. Pneumonitis rates before and after adoption of immunotherapy consolidation in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiation
39. Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer
40. Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLC
41. Pneumonitis Rates Before and After Adoption of Immunotherapy Consolidation in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation
42. Effect of Prophylactic Cranial Irradiation on Overall Survival in Metastatic Small-Cell Lung Cancer: A Propensity Score-Matched Analysis
43. Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non–Small-cell Lung Cancer: Results of a Phase II Study
44. The Role of Advanced Imaging in Assessing Response to Definitive Chemoradiation Before Prophylactic Cranial Irradiation in Limited-Stage Small-Cell Lung Cancer
45. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
46. The association between fatigue and pain symptoms and decreased physical activity after cancer
47. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy
48. Homologous recombination pathway gene variants identified by tumor-only sequencing assays in lung carcinoma patients
49. Functional Outcomes in Patients with Human Papillomavirus‐Associated Oropharyngeal Squamous Cell Cancer Treated with Trimodality Therapy
50. Prospective Feasibility and Phase I/II Trial of Preoperative Proton Beam Therapy with Concurrent Chemotherapy for Resectable Stage IIIA or Superior Sulcus Non-Small Cell Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.